MindMaze Therapeutics Holding SA

As of June 30, 2026, MindMaze Therapeutics Holding SA carries a market capitalization of 45.76M, placing it among publicly traded companies globally. Its enterprise value stands at 39.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MindMaze Therapeutics Holding SA's next confirmed earnings release is scheduled for April 15, 2027.

As of June 30, 2026, MindMaze Therapeutics Holding SA has 169.99M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MindMaze Therapeutics Holding SA maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, MindMaze Therapeutics Holding SA's stock has declined approximately 94.04% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 1.03.

As of June 30, 2026, MindMaze Therapeutics Holding SA holds 6.59M in cash and equivalents against 29,709.22 in total debt, resulting in a net debt position of -6.59M. Total book value stands at 44.48M, with working capital of 3.62M providing operational flexibility.

MindMaze Therapeutics Holding SA's most recent stock split took place on May 5, 2023 with a 400:1 split ratio.